Oncolytic biotherapy: A novel therapeutic platform

Lancet Oncology

Volumn 3, Issue 1, 2002, Pages 17-26

  Hawkins, Lynda K ^a   Lemoine, Nick R ^a   Kirn, David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOSINE DEAMINASE; FLUOROURACIL; FOLINIC ACID; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; NITROREDUCTASE; ONYX 015; PROSTATE SPECIFIC ANTIGEN; RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE; VIRUS VECTOR;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN TUMOR; CANCER RECURRENCE; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENTIATION; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION; HUMAN; HYPOXIA; MALIGNANT MESOTHELIOMA; MELANOMA; METASTASIS; MOUSE; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; REVIEW; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

EID: 0036161443     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00618-0     Document Type: Review

References (87)

1. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies
2. Reovirus as a novel oncolytic agent
3. Reovirus therapy of tumours with activated ras pathway
4. Inhibition by parvovirus H-1 of the formation of tumours in nude mice and colonies in vitro by transformed human mammary epithelial cells
5. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
6. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
7. Experimental therapy of human glioma by means of a genetically engineered virus mutant
8. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells
9. ONYX-015, an E1B gene-attenuated adenovirus, causes tumour-specific cytolysis and antitumoural efficacy that can be augmented by standard chemotherapeutic agents
10. An adenovirus E1A mutant that demonstrates potent and selective antitumoural efficacy
11. A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow
12. Identification of a conserved reseptor-binding site on the fiber proteins of CAR-recognizing adenoviridae
13. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
14. Adenovirus E1A-p105(Rb) protein interactions play a direct role in the initiation but not the maintenance of the rodent cell transformed phenotype
15. Cancer cell cycles
16. The properties of p53 proteins selected for the loss of suppression of transformation
17. ONYX-015, an E1B gene-attenuated adenovirus, causes tumour-specific cytolysis and antitumoural efficacy that can be augmented by standard chemotherapeutic agents
18. Adenovirus E1A CR2 mutants as selectively-replicating agents for cancer
19. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines
20. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumour suppression pathways
21. p53 mutations in human cancers
22. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumour suppressor
23. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53
24. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
25. Conditionally replicating herpes viruses for cancer therapy
26. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors
27. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma
28. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
29. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
30. A tale of two trials: Selectively replicating herpesviruses for brain tumours
31. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
32. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207)
33. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207)
34. Systemic antitumour immunity in experimental brain tumour therapy using a multimutated, replication-competent herpes simplex virus
35. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy
36. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
37. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
38. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumours by a HSV-1 vector
39. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumour activity
40. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumours
41. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer
42. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumours
43. Poxiviridae: The viruses and their replication
44. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
45. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: Induction and potentiation of antitumour responses
46. Anti-tumour immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L)
47. Sensitization of tumour necrosis factor alpha-resistant human melanoma by tumour-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus
48. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
49. Intratumoural recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
50. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
51. Generation of tumouricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope
52. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumour immunotherapy
53. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo
54. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration
55. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
56. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue
57. Vaccinia as a vector for tumour-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant
58. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumour regression
59. Poxvirus vectors: Orphaned and underappreciated
60. Reoviruses
61. Intergeneric poliovirus recombinants for the treatment of malignant glioma
62. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants
63. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence
64. Vesicular stomatitis virus
65. Exploiting tumour-specific defects in the interferon pathway with a previously unknown oncolytic virus
66. Anaerobic bacteria as a gene delivery system that is controlled by the tumour microenvironment
67. Use of preferentially replicating bacteria for the treatment of cancer
68. Tumour-targeted Salmonella as a novel anticancer vector
69. Lipid A mutant salmonella with suppressed virulence and TNF-alpha induction retain tumour-targeting in vivo
70. VNP20009, a genetically modified Salmonella typhimurium: Anti-tumour efficacy, toxicology, and biodistribution in preclinical models
71. A controlled trial of ONYX-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer
72. Hepatic arterial infusion of a replication-selective adenovirus, ONYX-015: A phase I/II clinical trial
73. Endoscopic ultrasound-guided intratumoural injection of pancreatic carcinomas with a replication-selective adenovirus: A phase I/II clinical trial
74. Adenovirus 2 Ip+ locus codes for a 19 kd tumour antigen that plays an essential role in cell transformation
75. Deletion of the adenoviral E1B-19kD gene enhances tumour cell killing of a replicating adenoviral vector
76. Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells
77. Tumour-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
78. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
79. Replicating adenoviral gene therapy
80. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
81. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
82. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoural efficacy
83. A phase II/II trial of ONYX-015 administered by hepatic artery infusion to patients with colorectal carcinoma
84. Phase I dose-escalation trial of intravenous ONYX-015 in patients with refractory cancer
85. Replication-selective adenviruses as oncolytic agents
86. Immunomodulation of cancer: Potential use of replication-selective agents
87. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions